Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?

Area of Science:

• Rheumatology
• Pharmacology
• Genetics

Background:

• Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disorder characterized by recurrent episodes of fever and inflammation.
• Treatment resistance to standard colchicine preparations (film- or sugar-coated tablets) is a clinical challenge in managing FMF patients.
• Alternative pharmaceutical formulations may offer improved efficacy in resistant cases.

Purpose of the Study:

• To evaluate the effectiveness of switching to a compressed tablet formulation of colchicine in Turkish FMF patients resistant to coated preparations.
• To assess the impact of this pharmaceutical change on the frequency of FMF attacks.

Main Methods:

• A cohort of 50 Turkish adult FMF patients resistant to domestic colchicine preparations were switched to an imported compressed tablet formulation.
• Patients were not receiving anti-interleukin-1 or other biologic agents.
• Attack frequencies and daily colchicine doses were compared before and after the pharmaceutical preparation change.

Main Results:

• Switching to compressed colchicine tablets significantly reduced the annual attack frequency in FMF patients (p < 0.0001).
• Before the switch, 64% of patients experienced more than 7 attacks per year; after the switch, 88% experienced 0-3 attacks per year.
• The daily colchicine dose remained similar before and after the pharmaceutical change (p = 0.9).

Conclusions:

• Turkish FMF patients resistant to coated colchicine tablets may benefit from switching to compressed colchicine tablets.
• The improved efficacy might be attributed to differences in pharmacokinetic properties between colchicine preparations.
• This study highlights the importance of pharmaceutical formulation in optimizing FMF treatment outcomes.